#United States #Campbell #glaucoma #Myra Vision #Calibreye

Myra Vision Takes a Major Step in Glaucoma Treatment

Myra Vision, a notable player in medical innovation, has successfully enrolled its first patient in the ADAPT clinical study aimed at evaluating the Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System. This important milestone was announced on January 26, 2026, by the company, which is part of the Shifamed portfolio. The study marks a significant advancement in the company's efforts to improve glaucoma treatment pathways in the United States following its FDA approval in August 2025.

The Calibreye System

The Calibreye TGT Surgical System is designed to provide a customizable solution for managing intraocular pressure (IOP) in patients diagnosed with moderate to severe glaucoma. Dr. David Godfrey, who has conducted the initial treatment at the Glaucoma Associates of Texas, expressed enthusiasm about participating in the a ADAPT trial. He highlighted the groundbreaking nature of the Calibreye system, which distinctively allows for clinician-directed postoperative adjustments, enhancing individualized care for patients.

Study Details

The ADAPT study is a prospective, multicenter, non-randomized, open-label trial. Throughout its course, it aims to recruit up to 70 refractory glaucoma patients, focusing on a primary effectiveness endpoint over a 12-month duration. Essentially, the clinical trial will assess both the safety and effectiveness of the titratable glaucoma therapy system aimed at optimizing IOP outcomes for participants. The Calibreye aqueous shunt, once implanted, will facilitate slit lamp-based outflow adjustments, tailoring treatment to each patient's changing needs over time.

Ike Ahmed, M.D., a leading figure associated with the Alan S. Crandall Center for Glaucoma Innovation at the John A. Moran Eye Center, noted how gratifying it is to witness years of research and development progress into real-world clinical applications. He stated that titratable glaucoma therapy could significantly improve outcomes for a vast segment of patients who lack suitable solutions under existing treatment modalities.

Addressing Global Challenges

Globally, glaucoma is regarded as the leading cause of irreversible blindness, impacting approximately 80 million individuals. Given the lack of a definitive cure, both patients and caregivers are focused on controlling the progression of the disease primarily through effective IOP regulation. Standard treatments, including conventional surgeries like trabeculectomy and tube shunt implants, often do not allow for modifications that cater to individual patient situations.

Robert Chang, President and CEO of Myra Vision, commented, "We are excited to have successfully enrolled our first patient in the ADAPT clinical study. This marks a pivotal moment for our organization and a step toward delivering the Calibreye System to both physicians and patients alike." He noted that procedures like Calibreye are currently being explored for a small yet significant portion of patients requiring extensive pressure reduction, promising personalized control of IOP will enable better healthcare delivery for these underserved individuals.

Looking Ahead

It’s essential to note that the Calibreye System is still in the investigational stage and is not available for sale in the U.S. or internationally. Myra Vision, being an entity under Shifamed LLC, aims to pioneer advancements in the glaucoma treatment landscape, working toward solutions that promote safe, personalized IOP management while minimizing complex complications often associated with traditional treatment methods.

As the ADAPT study progresses, more attention will be focused on the efficacy of adjustable solutions for glaucoma management, potentially reshaping the future of ophthalmologic care.

For further information about Myra Vision and their innovative advancements in glaucoma treatment, visit www.myravision.com.